Gustave Roussy
Ranked 4th amongst the best specialized cancer centers worldwide, Gustave Roussy is the leading European cancer center. Specializing in rare and complex tumors, it delivers diagnostics and therapies to 50,000 patients will all types of cancer each year. It is also a major European hub for research and teaching, with up to 40% of Gustave Roussy patients participating in clinical trials. The institution embraces concepts such as “cross-boundary working” and “multi-disciplinary patient management” which were championed by the institution’s founder, Professor Gustave Roussy.
Two Gustave Roussy teams are participating in the PATH FOR YOUNG project.
The Cancer Survivorship team led by Ines Vaz-Luis. This research team focuses on delivering a new generation of cancer survivorship research outputs. By intercepting biology, psycho-social and technology challenges, believing that this research can foster a paradigmatic shift in survivorship care, towards a more personalized, participative, proactive, and equitable care. The overarching goal of this shift is to reduce cancer- and treatment-related symptom burden, improve length and quality of life (QOL) of cancer survivors and minimize the societal burden of cancer.
The OncoStat unit led by Stefan Michiels. (need to get description of oncostat from stefan michiels)
Role
Gustave Roussy researchers are participating in several of the PATH FOR YOUNG work packages. Gustave Roussy is leading work packages dedicated to optimizing patient co-creation and representation; to data management, statistical analysis plan and reporting; to analyses addressing needs specific to premenopausal patients; and to the analysis of the key study endpoints. Gustave Roussy will also be closely involved in project management throughout the duration of the PATH FOR YOUNG study.
Members
Maria Alice Franzoi
WP4 Leader
Maria Alice Franzoi is a Brazilian medical oncologist with expertise in digital health, implementation science, and breast cancer care delivery. She completed her training in internal medicine and oncology at Hospital das Clínicas de Porto Alegre, Brazil, followed by a fellowship and PhD in breast cancer oncology at the Jules Bordet Institute and Université Libre de Bruxelles. Currently, she serves as a research team leader within the Cancer Survivorship Unit at Gustave Roussy.
Her research aims to co-design with patients and providers and implement digital health pathways in oncology to achieve improved and equitable care. By reorganizing healthcare systems, her work empowers providers to better utilize health data and enables patients to take an active role in their care. She has led important initiatives in digital health, including the design and implementation of a remote symptom monitoring pathway using ePROs and nurse navigation in routine care across 110 hospitals in France and Belgium, as well as a proactive care model to support breast cancer survivors.
In addition, her research identifies key factors influencing patient adoption and engagement in digital health pathways, as well as the complexity of care. Dr. Franzoi is the principal investigator of clinical trials exploring innovative care models that incorporate digital therapeutics for self-management, the digital capture of patient-generated data, and tools facilitating data exchange for improved care coordination and equitable outcomes. She is also deeply committed to empowering patients to act as co-researchers in clinical trials and building infrastructures for decentralized, inclusive research.
Antonio Di Meglio
WP6 Leader
Antonio Di Meglio is a medical oncologist specializing in the care of breast cancer patients, with extensive experience as a clinical researcher in international academic settings. His training includes an advanced research fellowship in the Breast Oncology Program at the Dana-Farber Cancer Institute/Harvard Cancer Center, biostatistics and programming at the Harvard School of Public Health and Harvard Catalyst, and a PhD focused on the behavioral aspects of breast cancer during and after treatment at Université Paris-Saclay.
Since 2017, Antonio has been a physician-scientist at Gustave Roussy, contributing to the Cancer Survivorship Program by leading research on stratification algorithms to guide personalized survivorship care pathways. His research focuses on leveraging longitudinal and multimodal data—including biological markers and patient-reported outcomes (PROMs/PREMs)—with a primary focus on the CANcer TOxicity (CANTO) study (NCT01993498). As a member of the study's scientific committee, he advances efforts to improve the understanding, prediction, and management of long-term symptoms related to cancer treatments to preserve long-term Quality of Life.
As principal investigator or co-investigator on numerous academic research projects funded nationally and internationally, Antonio has made significant contributions to oncology research. His work has been presented at leading conferences, including the ASCO Annual Meeting, the San Antonio Breast Cancer Symposium, the ESMO Breast Cancer Congress, and the ESMO Congress. His original research has been published in high-impact journals, including Annals of Oncology and the Journal of Clinical Oncology.
Stefan Michiels
WP5 and WP7 Leader
"Pr. Stefan Michiels is Head of the Office of Biostatistics and Epidemiology of the Clinical Research Division of Gustave Roussy, and Head of Oncostat research team of CESP, INSERM U1018, University Paris-Saclay, Villejuif, France. His areas of expertise are clinical trials, meta-analyses, analysis of biomarkers and clinical prediction models in oncology.
Stefan holds a PhD in Biostatistics from the School of Public Health at the University Paris-Sud and Master Degrees in Statistics and in Applied Mathematics from the University of Leuven. His previous positions include the Université Libre de Bruxelles- Institut Jules Bordet (FNRS researcher, Belgium), the National Cancer Institute (France) and the University of Leuven (Belgium). He has authored around 300 peer-reviewed publications. He is currently a member of the editorial board of Annals of Oncology and NPJ Breast Cancer.